Samchundang Pharmaceutical Signs Exclusive Supply Agreement for Ailia Biosimilar in 9 European Countries

Samchundang Pharmaceutical announced on the 25th that it has signed an exclusive supply contract for Ailia biosimilars with nine Western European countries (the United Kingdom, Belgium, the Netherlands, Norway, Portugal, Sweden, Greece, Ireland, and Finland).

This contract is based on the condition of receiving 55% of the partner company's total sales. It is expected that Samchundang Pharmaceutical's position in the European market will be further strengthened. With this, Samchundang Pharmaceutical has established a sales network in major European markets including the United Kingdom, Germany, Spain, and Italy. In particular, it has secured a strong foothold for entering the UK market, the largest market in Europe.

A company representative stated, "The reason we were able to sign the contract under the best condition of receiving 55% of sales, which is a key term of this agreement, is that in the European market, Ailia PFS (Pre-filled Syringe) accounts for 90% of total sales, and Samchundang Pharmaceutical was the first in Europe to apply for EMA approval for the Ailia biosimilar PFS, thus securing the status of a first mover." He added, "Compared to other competitors, we have superior price competitiveness and there is no possibility of infringing on the original patent."

The representative also added, "Among global Ailia biosimilar developers, except for companies with direct sales systems, Samchundang Pharmaceutical is the only one that has signed contracts with major advanced countries such as Europe, Canada, and Japan, which further proves this point."

Samchundang Pharmaceutical achieved a total contract amount and milestones of 50 million euros (approximately 70 billion KRW), including contracts with five European countries last November. The company explained that it has achieved the targeted contract amount and milestones in 14 countries excluding France, and the amount is expected to increase with additional country contracts.

The French market has recently seen increased potential for expansion due to the passage of a biosimilar preferential law. Additionally, since a separate marketing strategy is required, Samchundang Pharmaceutical is in the final stages of entering the French market under the most specialized conditions for this environment. The Eastern European region is also reported to be in the final stages of contract completion.

Including this contract, Samchundang Pharmaceutical has secured a total of 140 billion KRW in contract amounts and milestones from global contracts so far, with expected sales exceeding 6 trillion KRW, continuing rapid growth. Through this, the company plans to establish a dominant position in major advanced markets and further expand its influence in the global healthcare sector.

A company representative explained, "Along with France and the Eastern European region, the last remaining areas in Europe, we are also closely monitoring the patent dispute trends with local partners in the United States, the most important market in North America, while negotiating and establishing an early sales strategy." He added, "Once this contract is finalized, Samchundang Pharmaceutical will solidify its position in the European and North American markets, which together account for 80% of the global market, and this will serve as an important stepping stone to becoming a leader in the global biosimilar market."

This content was produced with the assistance of AI translation services.